Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus Infections, United States, 2010–11

Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
Emerging Infectious Diseases (Impact Factor: 6.75). 02/2012; 18(2):308-11. DOI: 10.3201/eid1802.111466
Source: PubMed


During October 2010-July 2011, 1.0% of pandemic (H1N1) 2009 viruses in the United States were oseltamivir resistant, compared with 0.5% during the 2009-10 influenza season. Of resistant viruses from 2010-11 and 2009-10, 26% and 89%, respectively, were from persons exposed to oseltamivir before specimen collection. Findings suggest limited community transmission of oseltamivir-resistant virus.

Download full-text


Available from: Larisa Gubareva, Oct 01, 2015
25 Reads
  • Source
    • "While resistant viruses related to the Newcastle cluster were detected in other parts of Australia [63, 64], fortunately, they did not spread internationally. However, reports from the UK [65], Netherlands [66], USA [67], and the Asia-Pacific [37] indicted an overall increase in the detection of oseltamivir-resistant viruses from untreated community patients around 2011, suggesting that A(H1N1)pdm09 H275Y variants may be becoming more capable of community transmission. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Antivirals play an important role in the prevention and treatment of influenza infections, particularly in high-risk or severely ill patients. Two classes of influenza antivirals have been available in many countries over the last decade (2004-2013), the adamantanes and the neuraminidase inhibitors (NAIs). During this period, widespread adamantane resistance has developed in circulating influenza viruses rendering these drugs useless, resulting in the reliance on the most widely available NAI, oseltamivir. However, the emergence of oseltamivir-resistant seasonal A(H1N1) viruses in 2008 demonstrated that NAI-resistant viruses could also emerge and spread globally in a similar manner to that seen for adamantane-resistant viruses. Previously, it was believed that NAI-resistant viruses had compromised replication and/or transmission. Fortunately, in 2013, the majority of circulating human influenza viruses remain sensitive to all of the NAIs, but significant work by our laboratory and others is now underway to understand what enables NAI-resistant viruses to retain the capacity to replicate and transmit. In this review, we describe how the susceptibility of circulating human and avian influenza viruses has changed over the last ten years and describe some research studies that aim to understand how NAI-resistant human and avian influenza viruses may emerge in the future.
    04/2014; 2014:430629. DOI:10.1155/2014/430629
  • Source
    • "This may be explained by the Taiwan CDC providing free antiviral agents since August 15, 2009. Despite a concern that oseltamivir overuse could select resistant viruses, studies that examined countries with high levels of oseltamivir use did not find a significant percentage of oseltamivir resistant influenza virus emerging during H1N1 pandemic [10-12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The Taiwan CDC provided free oseltamivir to all patients with influenza infections confirmed by rapid testing or who had clinical warning symptoms during the 2009 H1N1 influenza pandemic in Taiwan. However, oseltamivir utilization patterns, cost, and outcomes among oseltamivir-treated patients remained unclear. A population-level, observational cohort study was conducted using the Taiwan National Health Insurance Database from January to December 2009 to describe the use of oseltamivir.Result: Prescription trend over weeks increased after a change in government policy and responded to the influenza virus activity. The overall prescription rate was 22.33 per 1000 persons, with the highest prescription rate of 116.5 for those aged 7--12 years, followed by 69.0 for those aged 13--18 years, while the lowest rate was 1.7 for those aged >= 65 years. As influenza virus activity increased, the number of prescriptions for those aged <=18 years rose significantly, whereas no substantial change was observed for those aged >=65 years. There were also regional variations in terms of oseltamivir utilization and influenza complication rates. Oseltamivir was widely used in the 2009 H1N1 influenza pandemic in Taiwan, particularly in those aged 7--18 years. The number of prescriptions for oseltamivir increased with a change in government policy and with increasing cases of pandemic influenza. Further study is needed to examine whether there is an over- or under-use of anti-influenza drugs in different age groups or regions and to examine the current policy of public use of anti-influenza drugs to reduce influenza-associated morbidity and mortality.
    BMC Public Health 07/2013; 13(1):646. DOI:10.1186/1471-2458-13-646 · 2.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Enlightened by some flavonoid compounds, which had been found as influenza neuraminidase inhibitors, we designed and synthesized a series of novel compounds containing different amino acid fragments. We also reported a simple synthetic route from oseltamivir to prepare its active form which was used as the positive control. The result of enzyme inhibition assay indicated that all the designed compounds displayed weak inhibitory activity against neuraminidase. However, they showed moderate anti-avian H5N1 influenza virus activity in chick embryo. Besides interfering with the function of neuraminidase, these compounds seemed to inhibit the replication of influenza virus by some other mechanism which deserved deep study.
    Medicinal Chemistry Research 07/2012; 22(7). DOI:10.1007/s00044-012-0341-2 · 1.40 Impact Factor
Show more